A First-in-human Study Using BDC-1001 in Advanced and HER2-Expressing Solid Tumors

  • STATUS
    Recruiting
  • participants needed
    390
  • sponsor
    Bolt Biotherapeutics, Inc.
Updated on 19 February 2024
cancer
measurable disease
metastasis
solid tumour
pembrolizumab
solid tumor
advanced solid tumor
advanced malignant solid tumor
gene amplification
gastric tumor
exhausted
HER2

Summary

A first-in-human study using BDC-1001 in HER2 expressing advanced malignancies

Description

This study has four parts. Part 1 is a dose escalation of BDC-1001 as a single agent to determine the maximum tolerated dose (MTD) recommended for Part 3 and Phase 2 (RP2D). In Part 3, the selected dose will be administered as monotherapy to patients with selected advanced malignancies. Part 2 is a dose escalation of BDC-1001 in combination with pembrolizumab to determine the maximum tolerated dose (MTD) recommended for Part 4 and Phase 2 (RP2D). In Part 4, the selected dose will be administered in combination with pembrolizumab to patients with selected advanced malignancies.

Details
Condition Breast Cancer, Breast Cancer, Gastric Cancer, Gastric Cancer, Neoplasm, Metastatic
Age 18years - 100years
Treatment Pembrolizumab, BDC-1001
Clinical Study IdentifierNCT04278144
SponsorBolt Biotherapeutics, Inc.
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Patient must have an advanced solid tumor with documented HER2-protein expression or gene amplification for which approved therapies have been exhausted or are not clinically indicated
Measurable disease as determined by RECIST v.1.1
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Tumor tissue (archival or collected prior to the study start) available for exploratory biomarker evaluation

Exclusion Criteria

History of severe hypersensitivity to any ingredient of the study drug(s), including trastuzumab or other monoclonal antibody
Previous treatment with a TLR 7, TLR 8 or a TLR 7/8 agonist
For the combination portion of the study, previous treatment with an anti-PD1 or antiPD -L1 therapy
Impaired cardiac function or history of clinically significant cardiac disease
Human Immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection
Untreated central nervous system (CNS), epidural tumor or metastasis, or brain metastasis
Other protocol defined inclusion/exclusion criteria may apply
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.